Geron Q2 Revenue Jumps 17% to $57.5M; Loss Narrows; Cash Runway Extended
GERN sits 54% above its 52-week low of $1.04 on elevated volume (2.7× avg).
Summary
Geron reported Q2 2026 RYTELO net revenue of $57.5M, up 17% YoY, with a narrowed net loss and $326.9M in cash. The IMpactMF interim analysis is on track for H2 2026.
Key Events · Earnings and Guidance · GERN
-
RYTELO Revenue Growth Accelerates
Q2 2026 net product revenue reached $57.5M, a 17% increase over Q2 2025, driven by higher patient volumes and a modest price increase. H1 2026 revenue totaled $109.2M, up 24% year-over-year.
-
Loss Narrows; Cash Runway Solid
Net loss for Q2 was $16.7M, nearly flat YoY, while H1 loss improved to $20.3M from $36.2M. Cash, equivalents, and marketable securities stood at $326.9M as of June 30, 2026, sufficient for the foreseeable future.
-
IMpactMF Interim Analysis on Horizon
The Phase 3 IMpactMF trial in relapsed/refractory MF is fully enrolled; interim overall survival analysis is expected in the second half of 2026, a potential major value driver.
-
Debt Tranches Expire; No Additional Draws
The $75M Tranche B and $50M Tranche C loans under the Pharmakon agreement expired undrawn on July 30, 2026, leaving only the $125M Tranche A outstanding. This removes potential dilution but also limits additional debt capacity.
Analysis · GERN · Life Sciences
Geron's second-quarter results show accelerating commercial traction for RYTELO in lower-risk MDS, with net product revenue rising 17% year-over-year to $57.5 million. The company's net loss narrowed to $16.7 million from $16.4 million a year ago, and cash reserves of $326.9 million provide a comfortable runway. Management expects gross-to-net deductions to remain in the low-to-mid 20% range, a slight headwind. The upcoming interim overall survival analysis for the IMpactMF trial in relapsed/refractory myelofibrosis, expected in the second half of 2026, is the next major catalyst. The expiration of undrawn Tranche B and C loans removes potential dilution but also limits additional debt capacity. Ongoing securities litigation remains an overhang, though the company's motion to dismiss the second amended complaint is pending.
At the time of this filing, GERN was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.04 to $2.01. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.